Akebia Therapeutics (AKBA) Free Cash Flow (QoQ) (2013 - 2026)
Akebia Therapeutics (AKBA) Free Cash Flow (QoQ) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.19 Bn | 87.33 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.86 Bn | 32.12 Bn | 1.97 Bn |
| 3 | Zoetis | 32.52 Bn | 30.58 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.22 Bn | 21.07 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - |
| 7 | Viatris | 20.29 Bn | 18.48 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.72 Bn | 16.40 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.59 Bn | 12.16 Bn | 785.00 Mn |
| 10 | Akebia Therapeutics | 339.15 Mn | 176.55 Mn | 41.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -176.43% |
| Dec 31, 2025 | 2.50% |
| Sep 30, 2025 | 26.14% |
| Jun 30, 2025 | 263.31% |
| Mar 31, 2025 | -256.81% |
| Dec 31, 2024 | 46.88% |
| Sep 30, 2024 | 20.25% |
| Jun 30, 2024 | 55.10% |
| Mar 31, 2024 | -441.66% |
| Dec 31, 2023 | 138.24% |
| Sep 30, 2023 | -338.19% |
| Jun 30, 2023 | 131.65% |
| Mar 31, 2023 | 62.78% |
| Dec 31, 2022 | -330.92% |
| Sep 30, 2022 | 196.20% |
| Jun 30, 2022 | -39.42% |
| Mar 31, 2022 | 71.89% |
| Dec 31, 2021 | -3.85% |
| Sep 30, 2021 | -0.21% |
| Jun 30, 2021 | 13.02% |